RCT | Subcutaneous vs. transvenous implantable cardioverter defibrillator implantations.

Perioperative Safety and Early Patient and Device Outcomes Among Subcutaneous Versus Transvenous Implantable Cardioverter Defibrillator Implantations: A Randomized, Multicenter Trial – Annals of Internal Medicine (link to abstract – $ for full-text) 

News Release: S-ICD Associated with 92 Percent Reduction in Lead-Related Complications Typical in Patients with ICDs – American College of Physicians 

Commentaries: 

Subcutaneous ICD Reduces Lead-Related Complications – HealthDay 

Subcutaneous implantable cardioverter defibrillators reduce the risk of perioperative complications – Physician’s Weekly 

Related: 

Device-related complications in subcutaneous versus transvenous ICD: a secondary analysis of the PRAETORIAN trial – European Heart Journal 

Subcutaneous or Transvenous Defibrillator Therapy – New England Journal of Medicine 

Commentary on Twitter 

New from @PHRIresearch @McMasterU: S-ICDs reduce lead-related complications by 92% w/out compromising effectiveness of shocks, but trend towards more inappropriate shocks: https://t.co/i7TtRr0PqP pic.twitter.com/Jhp7uprJT7

— Annals of Int Med (@AnnalsofIM) November 8, 2022